In-House Counsel Forum on Government Regulation of Prescription Drug Pricing

American Conference Institute

Event Info

  • Date:

    6.28.2012

  • Time:

    11:00 am - 12:00 pm EST

  • Location:

    New York, NY

Topics

  • The Status, Evolution and Continued Significance of AWP Litigation
    (William A. Davis, Panelist )

Bill Davis will speak on the panel, "The Status, Evolution and Continued Significance of AWP Litigation," at the 10th Annual In-House Counsel Forum on Government Regulation of Prescription Drug Pricing presented by the American Conference Institute in New York City.

The panel will discuss the following topics:

  • Review of the current status of MDL 1465, i.e., In Re Pharmaceutical Average Wholesale Price Litigation
  • Examining the effect of AWP litigation on the continued use of the AWP pricing methodology
    - what conclusions have finally been drawn about spread between AWP and actual purchase price?
    - how may these conclusions deter the potential creation of a ‘new spread’ through the use of different pricing methodologies
  • Evolution of AWP cases
    - shift from physician administered drugs to self administered drugs
  • Update on state AWP cases
    - deciphering how AWP data is still being derived relative to information still supplied from First
    Databank
    - review of state cases which have been brought under different pricing methodologies
    - high profile state AWP actions
  • Revisiting the private/public interface in these cases, e.g., suits brought by individuals, unions and consumer groups
    - state consumer protection statutes
    - state false claims act statutes
  • Understanding the role of private law firms acting on behalf of state AGs in these matters
  • Predicting future trends in the course of these suits

Panel
William A. Davis, Member, Mintz Levin
Michael L. Koon, Partner, Shook, Hardy & Bacon
Katy E. Koski, Partner, K&L Gates

Event Details
The Status, Evolution and Continued Significance of AWP Litigation